GAMMA Investing LLC Has $74,000 Position in BioNTech SE (NASDAQ:BNTX)

GAMMA Investing LLC boosted its position in shares of BioNTech SE (NASDAQ:BNTX) by 21.7% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 623 shares of the company’s stock after buying an additional 111 shares during the quarter. GAMMA Investing LLC’s holdings in BioNTech were worth $74,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of BNTX. Virtu Financial LLC bought a new position in BioNTech in the fourth quarter valued at about $274,000. Goldman Sachs Group Inc. grew its position in shares of BioNTech by 17.2% during the 4th quarter. Goldman Sachs Group Inc. now owns 182,878 shares of the company’s stock worth $19,301,000 after buying an additional 26,777 shares during the period. PNC Financial Services Group Inc. raised its stake in shares of BioNTech by 207.5% during the fourth quarter. PNC Financial Services Group Inc. now owns 2,583 shares of the company’s stock worth $273,000 after buying an additional 1,743 shares during the last quarter. Green Alpha Advisors LLC raised its stake in shares of BioNTech by 12.9% during the first quarter. Green Alpha Advisors LLC now owns 5,819 shares of the company’s stock worth $537,000 after buying an additional 666 shares during the last quarter. Finally, American National Bank bought a new position in BioNTech in the first quarter valued at approximately $81,000. 15.52% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts have commented on BNTX shares. HSBC upped their target price on shares of BioNTech from $97.00 to $136.00 and gave the company a “buy” rating in a research report on Monday, October 7th. JPMorgan Chase & Co. raised BioNTech from an “underweight” rating to a “neutral” rating and increased their target price for the company from $91.00 to $125.00 in a research note on Monday, September 16th. Bank of America boosted their target price on BioNTech from $125.00 to $150.00 and gave the stock a “buy” rating in a research report on Monday, September 16th. Deutsche Bank Aktiengesellschaft increased their price target on shares of BioNTech from $95.00 to $150.00 and gave the company a “buy” rating in a research report on Thursday, September 19th. Finally, UBS Group boosted their price objective on shares of BioNTech from $97.00 to $131.00 and gave the company a “neutral” rating in a report on Wednesday, September 18th. Five research analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, BioNTech has a consensus rating of “Moderate Buy” and an average price target of $131.92.

BioNTech Stock Performance

BNTX opened at $117.53 on Wednesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.54 and a quick ratio of 7.40. The company has a market capitalization of $27.94 billion, a price-to-earnings ratio of 235.06 and a beta of 0.24. The business’s 50-day moving average price is $102.50 and its two-hundred day moving average price is $93.74. BioNTech SE has a 1 year low of $76.53 and a 1 year high of $131.49.

BioNTech (NASDAQ:BNTX) last released its earnings results on Monday, August 5th. The company reported ($3.36) EPS for the quarter, missing the consensus estimate of ($2.02) by ($1.34). The firm had revenue of $128.70 million during the quarter, compared to the consensus estimate of $134.98 million. BioNTech had a negative net margin of 18.69% and a negative return on equity of 2.54%. The company’s revenue was down 23.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.86) EPS. Equities analysts expect that BioNTech SE will post -3.04 EPS for the current fiscal year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.